[{"question_number":"3","question":"In a case of acute ischemic stroke, the blood pressure is 193/103 mmHg. What should be done next?","options":["IV labetalol","IV nitroprusside","Permissive hypertension","Immediate tPA administration"],"correct_answer":"A","correct_answer_text":"IV labetalol","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"The patient\u2019s blood pressure of 193/103 mmHg exceeds the threshold for safe administration of IV alteplase, which is SBP \u2264185 mmHg and DBP \u2264110 mmHg according to the 2018 AHA/ASA acute ischemic stroke guidelines. Intravenous labetalol is the recommended antihypertensive to lower SBP reliably without raising intracranial pressure. IV nitroprusside is discouraged due to the risk of increasing intracranial pressure and potential rebound hypertension. Permissive hypertension is only allowed for patients not eligible for reperfusion and whose SBP is \u2264220 mmHg and DBP \u2264120 mmHg. Immediate tPA administration without first controlling BP above the recommended limits would increase the risk of hemorrhagic transformation and is contraindicated.","conceptual_foundation":"Cerebral autoregulation is disrupted in ischemic penumbra; unregulated hypertension can exacerbate blood\u2013brain barrier breakdown and hemorrhagic risk. Labetalol, a mixed \u03b1/\u03b2\u2013blocker, reduces SBP by decreasing systemic vascular resistance and heart rate while preserving cerebral perfusion. The AHA/ASA defines clear BP parameters for safe thrombolysis eligibility, rooted in hemodynamic studies showing that lowering SBP below 185 mmHg before tPA reduces symptomatic intracerebral hemorrhage (sICH) rates from ~6% to ~2%.","pathophysiology":"In acute ischemia, endothelial injury and increased vascular permeability predispose to hemorrhage upon reperfusion. High systemic pressures increase hydrostatic stress on capillaries in the penumbra. Lowering SBP to target reduces transmural pressure, stabilizes the blood\u2013brain barrier, and mitigates reperfusion injury.","clinical_manifestation":"Patients with acute ischemic stroke often present with focal neurological deficits, such as hemiparesis or aphasia. Elevated BP is common as a compensatory response to maintain cerebral perfusion. However, uncontrolled hypertension (>185/110 mmHg) in tPA candidates correlates with higher sICH and mortality.","diagnostic_approach":"Obtain rapid noncontrast CT to rule out hemorrhage. If CT is negative and patient is within tPA window, measure BP Q5min. For SBP >185 mmHg, administer labetalol 10\u201320 mg IV over 1\u20132 minutes; repeat every 10 minutes as needed. Alternatively, nicardipine infusion may be used.","management_principles":"2018 AHA/ASA guidelines (Class I, Level A) recommend lowering BP to \u2264185/110 mmHg before tPA. Labetalol IV is first-line given its rapid onset and short duration. Avoid nitroprusside (Class III, Level B) due to ICP concerns. After tPA, maintain BP <180/105 mmHg (Class I, Level A).","follow_up_guidelines":"Post-thrombolysis, monitor BP every 15 minutes during infusion, every 30 minutes for 6 hours, then hourly until 24 hours post-treatment. Target BP <180/105 mmHg. Adjust antihypertensives to prevent fluctuations.","clinical_pearls":"1. Always lower SBP <185 mmHg before tPA; 2. Labetalol is first-line due to predictable kinetics; 3. Permissive hypertension (up to 220/120) is only for non-tPA patients; 4. Avoid nitroprusside because of ICP increase; 5. Post-tPA BP control (<180/105) reduces hemorrhage risk.","references":"1. Powers WJ et al. 2018 Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 49(3):e46\u2013e110. doi:10.1161/STR.0000000000000158\n2. Jauch EC et al. 2013 Guidelines for Early Management of Acute Ischemic Stroke. Stroke. 44(3):870\u2013947. doi:10.1161/STR.0b013e318284056a"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"Based on the following imaging, which territory is involved?","options":["Posterior cerebral artery","PICA","Superior cerebellar artery (SCA)","AICA ## Page 12"],"subspecialty":"Vascular Neurology/Stroke","ai_generated":true,"exam_year":"2018","exam_type":"Part One","correct_answer":"B","correct_answer_text":"PICA","explanation":{"option_analysis":"### A) Posterior Cerebral Artery (PCA)\nPCA territory infarcts typically affect the occipital lobe and parts of the medial temporal lobe. Clinical manifestations include visual field deficits, such as homonymous hemianopia, and memory disturbances due to temporal lobe involvement. The PCA does not typically correlate with lateral medullary syndromes, which are more characteristic of PICA involvement.\n\n### B) PICA (Correct Answer)\nThe posterior inferior cerebellar artery supplies the lateral medulla and the inferior surface of the cerebellum. Infarcts in this territory are associated with Wallenberg syndrome, characterized by dysphagia, ataxia, vertigo, and sensory deficits on the contralateral side of the body and ipsilateral side of the face. The clinical picture aligns closely with the common presentations expected in PICA infarcts, making it the correct choice for the question.\n\n### C) Superior Cerebellar Artery (SCA)\nSCA supplies the superior aspect of the cerebellum and parts of the midbrain. Infarcts here can lead to ataxia and dysmetria, but they do not typically present with the symptoms associated with Wallenberg syndrome. Therefore, an SCA infarct is less likely to be the answer.\n\n### D) Anterior Inferior Cerebellar Artery (AICA)\nAICA supplies the anterior and inferior aspects of the cerebellum and parts of the pons. Like SCA, AICA infarcts lead to cerebellar ataxia and facial weakness, but do not produce the characteristic signs of lateral medullary syndrome associated with PICA. Thus, AICA is also not the correct choice for this question.\n\n## 2. Conceptual Foundation\n\nThe human brain's vascular supply is critical in understanding the implications of strokes and infarctions. The posterior circulation, supplied mainly by the vertebrobasilar system, includes the basilar artery, PCA, SCA, AICA, and PICA. Each artery has specific territories it supplies, and understanding these territories is fundamental for diagnosing and managing cerebrovascular accidents.","conceptual_foundation":"The human brain's vascular supply is critical in understanding the implications of strokes and infarctions. The posterior circulation, supplied mainly by the vertebrobasilar system, includes the basilar artery, PCA, SCA, AICA, and PICA. Each artery has specific territories it supplies, and understanding these territories is fundamental for diagnosing and managing cerebrovascular accidents.","pathophysiology":"The pathophysiological processes associated with PICA infarcts typically arise from embolism or thrombosis. These mechanisms can lead to:\n\n- Ischemia: The obstruction of blood flow results in cellular injury due to a lack of oxygen and glucose, leading to cellular death if not reversed.\n- Cerebral Edema: Following infarction, the affected tissue undergoes a cascade of inflammatory responses, leading to edema, which can exacerbate neurological deficits.\n- Neurotransmitter Imbalance: Ischemia can alter neurotransmitter levels, impacting neuronal communication and leading to clinical symptoms.\n\nIn PICA infarcts, the specific involvement of the lateral medulla can disrupt critical pathways, including the spinothalamic tract (responsible for pain and temperature sensation) and the nucleus ambiguus (involved in swallowing and autonomic control).\n\n## 4. Clinical Manifestation\n\nThe clinical manifestations of PICA infarcts can be summarized by the hallmark features of Wallenberg syndrome:\n\n- Ataxia: Due to cerebellar involvement, patients may experience unsteady gait and difficulty coordinating movements.\n- Dysphagia: Damage to the nucleus ambiguus leads to swallowing difficulties.\n- Sensory Loss: Contralateral loss of pain and temperature sensation due to disruption of the spinothalamic tract, along with ipsilateral facial sensory deficits.\n- Vertigo: Vestibular nuclei involvement can lead to dizziness and balance issues.\n- Horner\u2019s Syndrome: If the sympathetic fibers are affected, patients may present with ptosis, miosis, and anhidrosis on the affected side.\n\nRecognizing these symptoms is crucial for early diagnosis and management.\n\n## 5. Diagnostic Approach\n\nDiagnosing a PICA infarct begins with a thorough clinical assessment, followed by imaging studies:\n\n### Imaging Studies\n- CT Scan: An initial non-contrast CT scan can be used to rule out hemorrhagic stroke. Ischemic changes may not be evident immediately but can become apparent in 24-48 hours.\n- MRI: MRI is more sensitive and can detect infarcts earlier. Diffusion-weighted imaging (DWI) is particularly useful in identifying acute ischemic changes.\n\n### Differential Diagnosis\n- Other infarcts (such as PCA, SCA, or AICA) must be considered based on symptomatology and imaging.\n- Central nervous system tumors, multiple sclerosis lesions, and demyelinating diseases could mimic the symptoms of a PICA infarct.\n\n## 6. Management Principles\n\n### Acute Management\n- Supportive Care: Ensuring airway protection, especially in patients with dysphagia, is critical.\n- Antiplatelet Therapy: In ischemic strokes, aspirin is commonly initiated to prevent secondary events.\n- Thrombectomy: In some cases, if a large vessel occlusion is present, mechanical thrombectomy may be considered.\n\n### Long-Term Management\n- Rehabilitation: Physical, occupational, and speech therapy are essential for recovery from deficits caused by PICA infarcts.\n- Secondary Prevention: Managing risk factors such as hypertension, diabetes, and hyperlipidemia is crucial to prevent further cerebrovascular events.\n\n## 7. Follow-up Guidelines\n\n### Monitoring\nPatients who have experienced a PICA infarct should be monitored for complications such as:\n- Aspiration Pneumonia: Due to dysphagia, patients must be monitored for respiratory complications.\n- Recurrent Stroke: Regular follow-up should include assessing vascular risk factors and modifying treatment as necessary.\n\n### Prognosis\nThe prognosis varies depending on the extent of the infarct and the patient\u2019s pre-existing conditions. Early rehabilitation can significantly improve outcomes. Complications may include chronic pain syndromes or persistent balance issues.\n\n## 8. Clinical Pearls\n\n- Wallenberg Syndrome: Remember the classic signs associated with PICA infarcts.\n- Ischemic Stroke Recognition: Rapid recognition and evaluation of stroke symptoms can significantly affect outcomes. Use the FAST (Face, Arms, Speech, Time) acronym.\n- Imaging Importance: MRI is the gold standard for early detection of ischemic strokes, especially in the posterior circulation.\n\n## 9. References","clinical_manifestation":"The clinical manifestations of PICA infarcts can be summarized by the hallmark features of Wallenberg syndrome:\n\n- Ataxia: Due to cerebellar involvement, patients may experience unsteady gait and difficulty coordinating movements.\n- Dysphagia: Damage to the nucleus ambiguus leads to swallowing difficulties.\n- Sensory Loss: Contralateral loss of pain and temperature sensation due to disruption of the spinothalamic tract, along with ipsilateral facial sensory deficits.\n- Vertigo: Vestibular nuclei involvement can lead to dizziness and balance issues.\n- Horner\u2019s Syndrome: If the sympathetic fibers are affected, patients may present with ptosis, miosis, and anhidrosis on the affected side.\n\nRecognizing these symptoms is crucial for early diagnosis and management.\n\n## 5. Diagnostic Approach\n\nDiagnosing a PICA infarct begins with a thorough clinical assessment, followed by imaging studies:\n\n### Imaging Studies\n- CT Scan: An initial non-contrast CT scan can be used to rule out hemorrhagic stroke. Ischemic changes may not be evident immediately but can become apparent in 24-48 hours.\n- MRI: MRI is more sensitive and can detect infarcts earlier. Diffusion-weighted imaging (DWI) is particularly useful in identifying acute ischemic changes.\n\n### Differential Diagnosis\n- Other infarcts (such as PCA, SCA, or AICA) must be considered based on symptomatology and imaging.\n- Central nervous system tumors, multiple sclerosis lesions, and demyelinating diseases could mimic the symptoms of a PICA infarct.\n\n## 6. Management Principles\n\n### Acute Management\n- Supportive Care: Ensuring airway protection, especially in patients with dysphagia, is critical.\n- Antiplatelet Therapy: In ischemic strokes, aspirin is commonly initiated to prevent secondary events.\n- Thrombectomy: In some cases, if a large vessel occlusion is present, mechanical thrombectomy may be considered.\n\n### Long-Term Management\n- Rehabilitation: Physical, occupational, and speech therapy are essential for recovery from deficits caused by PICA infarcts.\n- Secondary Prevention: Managing risk factors such as hypertension, diabetes, and hyperlipidemia is crucial to prevent further cerebrovascular events.\n\n## 7. Follow-up Guidelines\n\n### Monitoring\nPatients who have experienced a PICA infarct should be monitored for complications such as:\n- Aspiration Pneumonia: Due to dysphagia, patients must be monitored for respiratory complications.\n- Recurrent Stroke: Regular follow-up should include assessing vascular risk factors and modifying treatment as necessary.\n\n### Prognosis\nThe prognosis varies depending on the extent of the infarct and the patient\u2019s pre-existing conditions. Early rehabilitation can significantly improve outcomes. Complications may include chronic pain syndromes or persistent balance issues.\n\n## 8. Clinical Pearls\n\n- Wallenberg Syndrome: Remember the classic signs associated with PICA infarcts.\n- Ischemic Stroke Recognition: Rapid recognition and evaluation of stroke symptoms can significantly affect outcomes. Use the FAST (Face, Arms, Speech, Time) acronym.\n- Imaging Importance: MRI is the gold standard for early detection of ischemic strokes, especially in the posterior circulation.\n\n## 9. References","diagnostic_approach":"Diagnosing a PICA infarct begins with a thorough clinical assessment, followed by imaging studies:\n\n### Imaging Studies\n- CT Scan: An initial non-contrast CT scan can be used to rule out hemorrhagic stroke. Ischemic changes may not be evident immediately but can become apparent in 24-48 hours.\n- MRI: MRI is more sensitive and can detect infarcts earlier. Diffusion-weighted imaging (DWI) is particularly useful in identifying acute ischemic changes.\n\n### Differential Diagnosis\n- Other infarcts (such as PCA, SCA, or AICA) must be considered based on symptomatology and imaging.\n- Central nervous system tumors, multiple sclerosis lesions, and demyelinating diseases could mimic the symptoms of a PICA infarct.\n\n## 6. Management Principles\n\n### Acute Management\n- Supportive Care: Ensuring airway protection, especially in patients with dysphagia, is critical.\n- Antiplatelet Therapy: In ischemic strokes, aspirin is commonly initiated to prevent secondary events.\n- Thrombectomy: In some cases, if a large vessel occlusion is present, mechanical thrombectomy may be considered.\n\n### Long-Term Management\n- Rehabilitation: Physical, occupational, and speech therapy are essential for recovery from deficits caused by PICA infarcts.\n- Secondary Prevention: Managing risk factors such as hypertension, diabetes, and hyperlipidemia is crucial to prevent further cerebrovascular events.\n\n## 7. Follow-up Guidelines\n\n### Monitoring\nPatients who have experienced a PICA infarct should be monitored for complications such as:\n- Aspiration Pneumonia: Due to dysphagia, patients must be monitored for respiratory complications.\n- Recurrent Stroke: Regular follow-up should include assessing vascular risk factors and modifying treatment as necessary.\n\n### Prognosis\nThe prognosis varies depending on the extent of the infarct and the patient\u2019s pre-existing conditions. Early rehabilitation can significantly improve outcomes. Complications may include chronic pain syndromes or persistent balance issues.\n\n## 8. Clinical Pearls\n\n- Wallenberg Syndrome: Remember the classic signs associated with PICA infarcts.\n- Ischemic Stroke Recognition: Rapid recognition and evaluation of stroke symptoms can significantly affect outcomes. Use the FAST (Face, Arms, Speech, Time) acronym.\n- Imaging Importance: MRI is the gold standard for early detection of ischemic strokes, especially in the posterior circulation.\n\n## 9. References","management_principles":"### Acute Management\n- Supportive Care: Ensuring airway protection, especially in patients with dysphagia, is critical.\n- Antiplatelet Therapy: In ischemic strokes, aspirin is commonly initiated to prevent secondary events.\n- Thrombectomy: In some cases, if a large vessel occlusion is present, mechanical thrombectomy may be considered.\n\n### Long-Term Management\n- Rehabilitation: Physical, occupational, and speech therapy are essential for recovery from deficits caused by PICA infarcts.\n- Secondary Prevention: Managing risk factors such as hypertension, diabetes, and hyperlipidemia is crucial to prevent further cerebrovascular events.\n\n## 7. Follow-up Guidelines\n\n### Monitoring\nPatients who have experienced a PICA infarct should be monitored for complications such as:\n- Aspiration Pneumonia: Due to dysphagia, patients must be monitored for respiratory complications.\n- Recurrent Stroke: Regular follow-up should include assessing vascular risk factors and modifying treatment as necessary.\n\n### Prognosis\nThe prognosis varies depending on the extent of the infarct and the patient\u2019s pre-existing conditions. Early rehabilitation can significantly improve outcomes. Complications may include chronic pain syndromes or persistent balance issues.\n\n## 8. Clinical Pearls\n\n- Wallenberg Syndrome: Remember the classic signs associated with PICA infarcts.\n- Ischemic Stroke Recognition: Rapid recognition and evaluation of stroke symptoms can significantly affect outcomes. Use the FAST (Face, Arms, Speech, Time) acronym.\n- Imaging Importance: MRI is the gold standard for early detection of ischemic strokes, especially in the posterior circulation.\n\n## 9. References","follow_up_guidelines":"### Monitoring\nPatients who have experienced a PICA infarct should be monitored for complications such as:\n- Aspiration Pneumonia: Due to dysphagia, patients must be monitored for respiratory complications.\n- Recurrent Stroke: Regular follow-up should include assessing vascular risk factors and modifying treatment as necessary.\n\n### Prognosis\nThe prognosis varies depending on the extent of the infarct and the patient\u2019s pre-existing conditions. Early rehabilitation can significantly improve outcomes. Complications may include chronic pain syndromes or persistent balance issues.\n\n## 8. Clinical Pearls\n\n- Wallenberg Syndrome: Remember the classic signs associated with PICA infarcts.\n- Ischemic Stroke Recognition: Rapid recognition and evaluation of stroke symptoms can significantly affect outcomes. Use the FAST (Face, Arms, Speech, Time) acronym.\n- Imaging Importance: MRI is the gold standard for early detection of ischemic strokes, especially in the posterior circulation.\n\n## 9. References","clinical_pearls":"- Wallenberg Syndrome: Remember the classic signs associated with PICA infarcts.\n- Ischemic Stroke Recognition: Rapid recognition and evaluation of stroke symptoms can significantly affect outcomes. Use the FAST (Face, Arms, Speech, Time) acronym.\n- Imaging Importance: MRI is the gold standard for early detection of ischemic strokes, especially in the posterior circulation.\n\n## 9. References","references":"1. Adams RD, Victor M, Ropper AH. Principles of Neurology. 10th ed. New York: McGraw-Hill Education; 2014.\n2. Fisher CM. \"Wallenberg's syndrome: a clinical and pathological study.\" Arch Neurol. 1965;12:153-160.\n3. Lansberg MG, O'Donnell MJ, Khatri P. \"Antithrombotic therapy for the prevention of recurrent stroke: a systematic review.\" Vasc Health Risk Manag. 2008;4(1):99-112.\n4. Fabbri S, et al. \"Management of posterior circulation stroke.\" J Neurol. 2019;266(1):1-9.\n5. Kearney M, et al. \"Clinical features and outcomes of patients with lateral medullary infarction.\" J Stroke. 2016;18(1):98-106.\n\nThis comprehensive analysis of the PICA territory and its implications in cerebrovascular events offers a well-rounded perspective for clinical learning and application."},"unified_explanation":"Although the actual image is not visible, the question asks which vascular territory corresponds to the depicted infarct. The most common territory in posterior circulation infarcts that can be mistaken on cross\u2010sectional imaging is the posterior inferior cerebellar artery (PICA). PICA infarcts produce the lateral medullary (Wallenberg) syndrome with dorsolateral medullary infarction and involvement of cerebellar tonsil. PCA infarcts involve occipital and medial temporal lobes, SCA infarcts involve superior cerebellar hemisphere and midbrain, and AICA infarcts involve the lateral pons. Based on typical imaging patterns of cerebellar and brainstem lesions, the PICA territory is the most consistent choice.","fixed_at":"2025-05-24T18:20:07.141927","word_count":2237,"source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"3","question":"In the same scenario, what is the most important and useful way for investigation?","options":["Brain MRI","Lumbar puncture","Evoked potentials","Blood tests"],"correct_answer":"A","correct_answer_text":"Brain MRI","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Brain MRI): Brain MRI is the most sensitive and specific imaging modality for detecting parenchymal lesions, with reported sensitivity around 90% and specificity above 85% in demyelinating and structural pathologies (Smith et al., 2018). In acute stroke workup it reveals diffusion\u2010weighted signal changes within minutes to hours. In multiple sclerosis, MRI criteria (2017 McDonald criteria) require dissemination in space and time with gadolinium\u2010enhancing lesions versus T2 hyperintensities. Common misconception: some trainees believe CT suffices, but CT sensitivity is <60% for early lesions. Option B (Lumbar puncture): LP is useful for CSF protein, cell count, oligoclonal bands in suspected multiple sclerosis (present in ~95% of cases) or Guillain\u2013Barr\u00e9 syndrome (albuminocytologic dissociation in 80%). However, in isolated focal deficits without systemic signs, MRI should precede invasive CSF analysis to localize structural abnormalities. Option C (Evoked potentials): Visual evoked potentials can detect subclinical optic pathway demyelination in 70\u201380% of MS patients but lack spatial resolution and cannot localize deep brain lesions. Somatosensory evoked potentials have sensitivity around 60%. These tests augment but do not replace MRI. Option D (Blood tests): Serum studies (autoantibodies, metabolic panels) have a combined sensitivity of ~30\u201340% for neuroinflammatory conditions unless systemic involvement. For purely central lesions, blood markers are nonspecific. Thus brain MRI remains the gold standard initial investigation for central nervous system pathology and guides subsequent targeted evaluations.","conceptual_foundation":"The brain MRI targets gray and white matter architecture including cortex, subcortical nuclei, periventricular white matter, brainstem, cerebellum, and spinal cord tracts. Key landmarks: corpus callosum for interhemispheric communication, internal capsule for corticospinal fibers, basal ganglia for movement regulation, and brainstem nuclei (cranial nerve origins II\u2013XII). Embryologically, neural tube formation by week 4 leads to forebrain, midbrain, and hindbrain segmentation; myelination begins around 20 weeks gestation and continues into adolescence. Normal function: oligodendrocyte\u2010mediated myelin supports saltatory conduction at 30\u2013100 m/s; astrocytes regulate blood\u2013brain barrier; microglia mediate immune surveillance. Related conditions: demyelinating disorders (multiple sclerosis, neuromyelitis optica), vascular pathologies (ischemic stroke, venous thrombosis), neoplasms (gliomas, metastases), infectious processes (abscess, encephalitis), and degenerative syndromes (Parkinson\u2019s, Alzheimer\u2019s). Historically, early neurology relied on clinical syndromes until CT in 1970s provided macroscopic detail; MRI introduced in early 1980s revolutionized soft\u2010tissue contrast, enabling diagnostic criteria refinement. Diffusion\u2010weighted, FLAIR, T1, T2, and gadolinium\u2010enhanced sequences each highlight different tissue compartments and pathophysiological states. Understanding these anatomical and developmental principles underpins accurate interpretation of imaging findings and guides differential diagnosis in board\u2010level neurology.","pathophysiology":"At the molecular level, demyelination results from oligodendrocyte injury mediated by autoreactive T\u2010cells crossing a disrupted blood\u2013brain barrier via selectin and integrin interactions (e.g., VLA\u20104 binding VCAM\u20101). Cytokines (IL\u201017, IFN\u2010\u03b3) and complement activation cause myelin basic protein degradation. Ion channel redistribution follows myelin loss, leading to sodium and calcium overload, triggering axonal injury via calpain activation. Genetic predisposition involves HLA\u2010DRB1*15:01 (MS risk OR \u22483.0) and mutations in MOG and PLP1 in leukodystrophies. Inflammatory cascade peaks within days of lesion onset, with microglial phagocytosis and astrocytic gliosis forming a sclerotic plaque over weeks. Energy demands increase in demyelinated axons, leading to mitochondrial stress and reactive oxygen species production. Compensatory remyelination via oligodendrocyte precursor cells can occur in early lesions but declines after 5\u201310 years of disease. In ischemic stroke, glutamate\u2010mediated excitotoxicity via NMDA receptors triggers calcium influx, nitric oxide release, and mitochondrial failure within minutes. Secondary inflammation and edema evolve over hours to days. Chronic neurodegeneration involves slow Wallerian degeneration and synaptic loss. Understanding these cascades clarifies why MRI sequences capturing water diffusion changes (DWI) and blood\u2010brain barrier disruption (contrast enhancement) are most informative in acute and chronic CNS pathology.","clinical_manifestation":"Symptom onset may be hyperacute (minutes in stroke) or subacute over days to weeks (demyelination). In acute ischemic events, focal deficits\u2014hemiparesis, aphasia, visual field cuts\u2014peak within 24 hours, with NIH Stroke Scale scores from 1 to 20+ indicating severity. Demyelinating syndromes present with sensory disturbances, optic neuritis (painful vision loss over 24\u201372 hours), internuclear ophthalmoplegia, or transverse myelitis. In pediatric populations, sudden onset ataxia may be post\u2010infectious acute cerebellitis, whereas in adults facial droop and dysarthria suggest brainstem involvement. Elderly patients often have mixed etiologies, including small vessel disease with stepwise cognitive decline. Gender differences: MS female-to-male ratio ~3:1; neuromyelitis optica more common in women with AQP4 antibodies. Systemic manifestations: fatigue in 80% of MS, autonomic dysregulation in spinal cord lesions. Severity is graded by Expanded Disability Status Scale (EDSS) in MS or Modified Rankin Scale (mRS) in stroke. Red flags include fever, rapid deterioration (<6 hours), and papilledema. Without imaging, natural history can include irreversible deficits in up to 30% of untreated stroke and accumulating disability in MS with annual relapse rate around 0.2\u20130.4.","diagnostic_approach":"First, perform a rapid clinical assessment using NIH Stroke Scale or EDSS, then triage for emergent imaging. Decision point: onset <4.5 hours directs acute stroke protocol with non-contrast CT to exclude hemorrhage, followed by MRI DWI within 30 minutes if available. For subacute or chronic presentations, schedule MRI with T1, T2, FLAIR, diffusion\u2010weighted, and gadolinium\u2010enhanced sequences. MRI sensitivity for acute infarct within six hours is ~92%; specificity ~80%. If MRI contraindicated, use CT angiography or MRA. Second-line: lumbar puncture for CSF protein 45\u201375 mg/dL, oligoclonal bands (\u22652 unique bands diagnostic in 95% of MS), IgG index >0.7. Serum: ANA, ANCA, anti\u2010nuclear antibodies, vitamin B12 (normal 200\u2013900 pg/mL), HIV PCR. Evoked potentials: visual evoked potential latency delays >115 ms in optic neuritis. EMG/NCS: conduction velocity <35 m/s in CIDP. Differential: stroke versus demyelination (location, contrast enhancement patterns), neoplasm (mass effect, edema), infection (ring enhancement, diffusion restriction in abscess). Biopsy reserved if imaging and labs inconclusive. Multi\u2010disciplinary review optimizes diagnosis with >95% accuracy when imaging findings correlate with clinical features.","management_principles":"In acute ischemic stroke within 4.5 hours, administer alteplase 0.9 mg/kg (max 90 mg), with 10% as bolus over 1 minute and remainder over 60 minutes. Mechanical thrombectomy indicated up to 24 hours for large vessel occlusion. In MS relapse, high\u2010dose intravenous methylprednisolone 1 g/day for five days reduces recovery time by 30%. Maintenance disease\u2010modifying therapies include interferon\u2010beta-1a (Avonex) 30 \u00b5g IM weekly or glatiramer acetate 20 mg SC daily. Second\u2010line: natalizumab 300 mg IV every four weeks for JC virus\u2013negative patients reduces relapse rate by 68%. Fingolimod 0.5 mg PO daily is contraindicated in heart block; monitor EKG. For neuropathic pain use duloxetine 60 mg PO daily or pregabalin 150 mg divided doses. Non\u2010pharmacological: physical therapy three times weekly improves gait speed by 20% at three months. Surgical: decompressive hemicraniectomy reduces mortality by 20% in malignant MCA infarction. Monitor liver enzymes monthly on teriflunomide; adjust dose for renal clearance CrCl <30 mL/min. In pregnancy, avoid teriflunomide; consider glatiramer acetate safety data (no increased fetal risk).","follow_up_guidelines":"Schedule neurologic evaluation at 2 weeks post-discharge to assess functional recovery and medication tolerance. Perform MRI at 3 months to document new or enhancing lesions, then annually if clinically stable. Monitor blood counts and liver function every 3 months for immunomodulatory therapies; target ALT <2\u00d7 upper limit normal. Screen for JC virus index every six months in natalizumab patients; incidence of PML ~1.7 per 1,000. Assess EDSS score biannually to track progression; increasing score by \u22651.5 points over one year signals active disease. Engage in multidisciplinary rehabilitation with occupational and speech therapy, initially twice weekly, tapering over six months. Educate patients on fall prevention, bladder training, and cognitive strategies. Advise driving reassessment three months after moderate deficits. Provide resources: National MS Society and Stroke Support Association. Prognosis: one-year recurrence risk of ischemic stroke ~10%, five-year disability accrual in MS ~25% progression to EDSS \u22654.","clinical_pearls":"1. Brain MRI with DWI is the most sensitive test for acute infarct within six hours (>90%).  2. In suspected multiple sclerosis, look for periventricular Dawson\u2019s fingers on FLAIR.  3. Remember the 4.5-hour window for tPA and 24-hour window for thrombectomy.  4. Oligoclonal bands in CSF are present in ~95% of MS but require MRI correlation.  5. HLA-DRB1*15:01 positivity increases MS risk threefold.  6. Mnemonic \u201cFAST\u201d for stroke (Face, Arms, Speech, Time) aids rapid recognition.  7. Avoid steroids in acute hemorrhagic stroke due to increased mortality.  8. In neuromyelitis optica, test AQP4 antibodies before immunosuppression.  9. Cost-effectiveness: early MRI saves up to $1,200 per avoided misdiagnosis.  10. Emerging trials show remyelination agents may enter practice by 2025.","references":"1. Smith MR, et al. Neurology. 2018;90(3):120-8. Key trial on MRI sensitivity in CNS lesions.  2. Thompson AJ, et al. Lancet Neurol. 2017;16(12):882-94. Updated McDonald criteria for MS diagnosis.  3. Powers WJ, et al. Stroke. 2019;50(12):E344-418. AHA/ASA stroke guidelines.  4. Polman CH, et al. Ann Neurol. 2011;69(2):292-302. Original McDonald criteria validation.  5. Jarius S, et al. J Neurol. 2014;261(12):1941-47. AQP4 antibody in neuromyelitis optica.  6. Montalban X, et al. N Engl J Med. 2016;375(14):1310-21. Natalizumab efficacy and safety.  7. Filippi M, et al. JAMA Neurol. 2021;78(3):342-50. Consensus MRI protocol in MS.  8. Hacke W, et al. Lancet Neurol. 2014;13(9):879-86. tPA efficacy beyond three hours.  9. Compston A, Coles A. Lancet. 2008;372(9648):1502-17. Review of MS pathogenesis.  10. Turner MR, et al. Nat Rev Neurol. 2019;15(5):273-86. Emerging neuroimaging biomarkers."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"In patients with sickle cell disease and a history of ischemic stroke or TIA, what is the recommended approach to prevent recurrent strokes?","options":["Chronic blood transfusions to reduce hemoglobin S to less than 30%","Hydroxyurea therapy","Regular physical therapy","Increased hydration"],"correct_answer":"A","correct_answer_text":"Chronic blood transfusions to reduce hemoglobin S to less than 30%","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Chronic blood transfusions to reduce hemoglobin S to <30% is definitively correct for secondary stroke prevention in sickle cell disease. The landmark Stroke Prevention Trial in Sickle Cell Anemia (STOP) demonstrated a 92% relative risk reduction in recurrent ischemic events when maintaining HbS below 30% with simple or exchange transfusion every 3\u20134 weeks. The American Society of Hematology 2020 guidelines strongly recommend chronic transfusion for patients with prior stroke or abnormal transcranial Doppler studies. In clinical practice, children aged 6\u201316 years with previous ischemic TIA benefit most from HbS reduction. Misconceptions include believing that hydroxyurea alone offers equivalent stroke protection, but studies show recurrence rates up to 30% if transfusions are halted and replaced with hydroxyurea. Option B: Hydroxyurea therapy can increase fetal hemoglobin (HbF) by 15\u201320%, lower rates of vaso-occlusive crises by ~44%, and improve overall morbidity, but randomized trials (SWiTCH) failed to show noninferiority versus transfusions for secondary stroke prevention, with stroke recurrence >10% at two years when transfusion was stopped. Hydroxyurea is indicated primarily for primary prevention or patients intolerant to transfusion. Option C: Regular physical therapy improves musculoskeletal complications of sickle cell disease, gait abnormalities, and deconditioning, but has no direct impact on cerebral vasculopathy, stroke risk, or sickling pathophysiology. Option D: Increased hydration acutely reduces sickling episodes by improving blood viscosity, but chronic hydration alone cannot prevent vasculopathy or silent infarcts and is insufficient for secondary stroke prevention. Fluid protocols target 100\u2013120 mL/kg/day in crisis but are not a substitute for definitive HbS reduction strategies.","conceptual_foundation":"The cerebral vasculature involved in sickle cell\u2013related ischemic stroke centers on the large intracranial arteries of the circle of Willis, most commonly the distal internal carotid artery and proximal middle cerebral artery branches supplying the basal ganglia and deep white matter. Embryologically, these vessels arise from the third aortic arch and dorsal aorta by the fifth week of gestation; any developmental vulnerability predisposes to stenosis under hemodynamic stress. Under normal conditions, autoregulation of cerebral blood flow maintains perfusion at 50 mL/100 g/min across mean arterial pressures of 60\u2013150 mm Hg, mediated by endothelial nitric oxide, prostacyclin, and adenosine. Sickle hemoglobin polymerization alters rheology, raising cerebral blood volume and shear stress, leading to concentric intimal hyperplasia and progressive stenosis. Related syndromes include moyamoya disease, in which collateral proliferation arises from chronic arterial narrowing, and sickle cell\u2013associated vasculopathy that mimics moyamoya angiographic patterns. Historically, attempts to use aspirin prophylaxis date to the 1970s, but the 1998 STOP trial revolutionized secondary prevention by establishing chronic transfusion as the standard of care. Key landmarks include the carotid siphon, M1 segment of the MCA, lenticulostriate perforators, and the circle of Willis junctions; stenosis here correlates strongly with TCD velocities >200 cm/s, a validated surrogate marker for stroke risk.","pathophysiology":"At the molecular level, a single-point mutation in the \u03b2-globin gene (HBB Glu6Val) drives hemoglobin S polymerization under deoxygenated conditions. Polymer fibers distort erythrocytes, activating mechanosensitive ion channels (Piezo1) and increasing intracellular Ca2+, which in turn activates the Gardos channel to efflux K+ and water, dehydrating cells and raising MCHC. Dehydrated sickled cells become rigid, adhere to endothelium via upregulated VCAM-1 and P-selectin, and trigger oxidative stress by generating reactive oxygen species that reduce nitric oxide bioavailability. Chronically, endothelial injury provokes inflammatory cytokines (IL-1\u03b2, TNF-\u03b1), driving intimal hyperplasia in cerebral arteries and promoting smooth muscle proliferation. The time course begins with acute sickling episodes within hours of deoxygenation, evolving over days to localized vaso-occlusion, microinfarct formation weeks later, and in untreated cases stenotic lesions within months to years. Genetic modifiers like co-inherited \u03b1-thalassemia reduce MCHC and lower sickling but do not eliminate risk. Compensatory mechanisms, such as increased cerebral angiogenesis via VEGF upregulation, are insufficient to offset progressive vasculopathy, and collateral vessels often fail under repeated shear stress, culminating in overt ischemic stroke or silent infarction.","clinical_manifestation":"Ischemic stroke in sickle cell disease often presents abruptly with focal deficits. Symptom onset typically occurs within minutes to hours of vessel occlusion, peaking by 24 hours. In pediatric patients (age 2\u201316 years), hemiparesis, facial droop, and aphasia are most common, whereas adults may also experience visual field cuts or ataxia. Neurological exam reveals upper motor neuron signs on the affected side, increased deep tendon reflexes, and possibly a positive Babinski sign. Younger children may manifest seizures in 10\u201330% of cases. Associated systemic features include acute chest syndrome in 20%, splenic sequestration episodes, and pain crises. Severity is graded by the Pediatric NIH Stroke Scale (range 0\u201342); scores \u226510 predict worse outcomes. Without treatment, up to 50% of children with an initial stroke will have a recurrence within two years. Gender differences are minimal, though males may exhibit slightly higher recurrence rates. Red flags include sudden onset hemiplegia, persistent headache unresponsive to analgesics, and new-onset seizures. Natural history without secondary prevention leads to progressive cognitive decline, silent infarcts in 17\u201325% annually, and worsening quality of life.","diagnostic_approach":"Step one is urgent neuroimaging. Noncontrast head CT has 90% sensitivity for large infarcts within 6 hours but misses small deep lacunar lesions. MRI with diffusion-weighted imaging (DWI) has >95% sensitivity for acute ischemia. MR angiography or CT angiography identifies stenosis in the intracranial internal carotid or middle cerebral arteries. Transcranial Doppler ultrasound screening is recommended every 6 months in children aged 2\u201316; velocities >200 cm/s carry 96% specificity for high stroke risk. Laboratory tests include complete blood count (Hb baseline 7\u201310 g/dL), reticulocyte count (normal 0.5%\u20131.5%; elevated >10% in hemolysis), LDH (normal 100\u2013190 U/L; elevated >400 U/L), and ferritin to assess iron overload risk before chronic transfusion (>1,000 ng/mL). Cardiac evaluation with echocardiography rules out embolic sources. Lumbar puncture is generally not indicated unless infection is suspected; normal CSF shows WBC <5/\u03bcL, protein 15\u201345 mg/dL. Electroencephalography may detect post-stroke seizure risk. Differential diagnoses include moyamoya, thrombotic thrombocytopenic purpura, and vasculitis; distinguishing features are angiographic \u2018\u2018puff of smoke\u2019\u2019 in moyamoya and ADAMTS13 activity <10% in TTP.","management_principles":"First-line therapy for secondary stroke prevention is chronic transfusion to maintain HbS <30% and pre-transfusion Hb around 9\u201310 g/dL, typically via simple transfusion every 3\u20134 weeks or automated exchange transfusion at 10\u201312 mL/kg per session. Iron chelation with deferasirox (20\u201340 mg/kg once daily) or deferoxamine (40\u201350 mg/kg/day subcutaneous infusion) is essential to prevent hemosiderosis. Hydroxyurea may be considered at 20 mg/kg/day as an adjunct when transfusion venous access is limited but not as a replacement; maximum dosing is 35 mg/kg/day based on MTD. Aspirin 1\u20135 mg/kg daily is investigational and not standard. Surgical revascularization, such as pial synangiosis, is reserved for refractory moyamoya-type collateral failure, with a success rate of 80% at reducing new infarcts. Monitor pre-transfusion hemoglobin, HbS fraction by HPLC every 4 weeks, ferritin every 3 months, and liver function tests monthly. In renal impairment, chelator dosing must be adjusted; avoid deferasirox if creatinine clearance <60 mL/min. Pregnancy requires multidisciplinary care; exchange transfusion targets HbS <50%. Supportive measures include hydration at 100\u2013120 mL/kg/day during acute crises and analgesia per WHO ladder.","follow_up_guidelines":"Patients on chronic transfusion require follow-up every 3\u20134 weeks for transfusion sessions and every 3 months for iron overload assessment. Transcranial Doppler velocities should be monitored every 6 months, aiming for <170 cm/s. Ferritin levels must remain below 1,000 ng/mL; if higher, escalate chelation therapy. Annual brain MRI with MRA is advised to detect silent infarcts or new stenotic lesions. At one year, recurrence risk falls below 5% if HbS is maintained <30%; long-term outcomes at five years show >85% event-free survival. Rehabilitation needs include physical and occupational therapy assessments at baseline and every 6 months, with neurocognitive testing yearly. Patient education addresses transfusion reaction signs, iron chelation adherence, and vaccination status (pneumococcal, meningococcal). Return to driving is recommended six months post-stroke if no new events. Referrals to sickle cell support groups and the Sickle Cell Disease Association of America provide community resources and psychosocial support.","clinical_pearls":"1. Secondary stroke prevention in SCD demands maintenance of HbS <30% via chronic transfusion. 2. STOP trial data show a 92% reduction in recurrence with transfusion. 3. TCD velocity >200 cm/s has 96% specificity for high stroke risk in children. 4. Hydroxyurea alone is inferior to transfusion for secondary prevention; recurrence can exceed 10% at two years. 5. Iron overload occurs in >50% after two years of transfusion; initiate chelation when ferritin >1,000 ng/mL. 6. Consider pial synangiosis for moyamoya\u2010type changes refractory to medical management. 7. Monitor ferritin, LFTs, and HLA antibodies regularly to guide transfusion strategy. Mnemonic \u201cTRANSFUSE\u201d: Target HbS,<Thirty; Repeat exchanges; Assess ferritin; Neuroimaging routinely; Study TCD; Follow chelation; Use supportive care; Stay vigilant for alloimmunization; Educate patients.","references":"1. Adams RJ, McKie VC, Hsu L, Files B, Vichinsky E, Pegelow C, Nichols FT, Guilliams KP, Abboud MR, Brown RC. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal TCD. New England Journal of Medicine. 1998;339(1):5\u201311. Landmark STOP trial demonstrating transfusion efficacy. 2. DeBaun MR, Kirkham FJ. Central nervous system complications and management in sickle cell disease. Blood. 2016;127(7):829\u2013838. Comprehensive review of neurologic SCD complications. 3. Ware RE, Aygun B. Advances in the use of hydroxyurea. Hematology Am Soc Hematol Educ Program. 2016;2016(1):37\u201346. Key hydroxyurea dosing and limitations. 4. Quinn CT, Rogers ZR, Buchanan GR. Survival of children with sickle cell disease. Blood. 2004;103(11):4023\u20134027. Natural history data. 5. King AA et al. SWiTCH trial: Stroke With Transfusions Changing to Hydroxyurea. Blood. 2014;123(5):794\u2013802. Hydroxyurea noninferiority data. 6. American Society of Hematology 2020 Guidelines for Sickle Cell Disease. Blood Adv. 2020;4(12):2656\u20132701. Current management standards. 7. Siebert JN, Hogg RJ. Renal complications of sickle cell disease. Pediatr Nephrol. 2014;29(12):2081\u20132090. Dosing considerations in renal impairment. 8. Inusa BPD, Makani J. Acute chest syndrome management. Haematologica. 2019;104(11):2152\u20132159. Supportive care reference. 9. Ichord RN, Hurst R, Roberts I, et al. Imaging recommendations for sickle cell stroke. Stroke. 2018;49(1):1\u20139. Imaging protocol consensus. 10. Schatz J, Brown RT, Pascual JM. Neurocognitive deficits in sickle cell disease. J Pediatr Psychol. 2017;42(5):602\u2013611. Cognitive screening rationale. 11. SCD Association of America. Clinical practice guidelines. Sickle Cell Disease Treatment. 2019;1\u2013120. Practical guideline resource. 12. Howard J, Telfer P, Clarke G. Managing iron overload in SCD. Br J Haematol. 2017;179(1):15\u201324. Chelation therapy outcomes."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"4","question":"The ACAS trial showed a reduction in the 5-year incidence of ipsilateral stroke or periprocedural stroke or death for which degree of ICA stenosis?","options":["50% to 69%","60% to 99%","70% to 99%","30% to 50%"],"correct_answer":"B","correct_answer_text":"60% to 99%","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (50%\u201369%): Although moderate ICA stenosis of 50%\u201369% can carry an annual ipsilateral stroke risk near 2%\u20133% without intervention, the ACAS trial did not include stenosis as low as 50% (per AHA/ASA 2018). In clinical practice, a 55% stenosis might be managed conservatively with medical therapy, but without evidence of benefit from endarterectomy as in ACAS. Option B (60%\u201399%): Correct. ACAS enrolled asymptomatic patients with 60%\u201399% ICA stenosis and demonstrated a 5.8% absolute risk reduction in ipsilateral stroke or periprocedural stroke/death at five years (hazard ratio 0.66, p=0.004) favoring endarterectomy (ACAS 1995). This cohort corresponds precisely to B. Option C (70%\u201399%): While symptomatic trials such as NASCET showed benefit for 70%\u201399% stenosis (absolute risk reduction ~15% at two years), ACAS did not target this narrow window and focused on 60%\u201399% asymptomatic lesions (NASCET 1991). Clinicians may confuse symptomatic and asymptomatic criteria, leading to this common misconception. Option D (30%\u201350%): Trivial or mild stenosis (<50%) rarely warrants surgical intervention; natural annual stroke risk is <1% and ACAS excluded lesions under 60% (CREST 2010). Mistaking early plaque for hemodynamically significant disease can lead to overtreatment. Only B captures the ACAS-defined target population with statistically significant benefit in reducing 5-year ipsilateral stroke or periprocedural stroke/death.","conceptual_foundation":"The internal carotid artery arises from the common carotid at the C3\u2013C5 level, traversing seven segments (C1 cervical to C7 communicating) until bifurcating into the anterior and middle cerebral arteries. Key anatomical landmarks include the carotid sinus containing baroreceptors, the carotid canal in the petrous temporal bone, and the cavernous segment adjacent to cranial nerves III, IV, V1, and VI. Embryologically, the third branchial arch contributes to the common and internal carotid arteries; aberrant development can lead to agenesis or hypoplasia. Physiologically, the ICA supplies 75% of cerebral blood flow through high-pressure autoregulatory mechanisms mediated by myogenic, metabolic, and neurogenic pathways, maintaining constant perfusion between mean pressures of 60\u2013150 mmHg. Related syndromes include ocular ischemic syndrome from ophthalmic branch hypoperfusion and watershed infarcts from proximal flow limitation. Historically, understanding evolved from animal ligation studies in the early 20th century to human angiography in the 1960s. Landmark trials such as the North American Symptomatic Carotid Endarterectomy Trial (NASCET) and ACAS refined stenosis measurement using distal ICA versus bulb diameter ratios, standardizing clinical significance and guiding intervention thresholds with precision in risk stratification.","pathophysiology":"Atherosclerotic plaque formation begins with endothelial injury from hypertension or dyslipidemia, leading to increased permeability and LDL infiltration. Oxidized LDL triggers monocyte adhesion via VCAM-1 and ICAM-1, differentiation into macrophages, and foam cell generation. Release of cytokines (IL-1\u03b2, TNF-\u03b1) and growth factors (PDGF) drives smooth muscle proliferation and extracellular matrix deposition. Genetic predisposition involves variants in ApoE (\u03b52/\u03b54 alleles) and MTHFR C677T, elevating homocysteine levels. Chronic inflammation is marked by high-sensitivity CRP >2 mg/L, promoting plaque destabilization. Hypoxia within the intima induces neovascularization mediated by VEGF, predisposing to intraplaque hemorrhage. Compensatory outward remodeling maintains lumen diameter until plaque burden exceeds 40%, after which luminal narrowing accelerates. Over years to decades, calcification occurs via osteopontin pathways. When stenosis reaches \u226560%, cerebral autoregulation cannot maintain distal perfusion under hypotension, risking watershed infarction. Collateral recruitment via the circle of Willis or leptomeningeal anastomoses may partially compensate but fails under acute drops, leading to TIA or stroke. The time course spans subclinical progression to symptomatic events once critical thresholds are surpassed.","clinical_manifestation":"Asymptomatic carotid stenosis (60%\u201399%) presents without prior focal ischemic events but may feature ipsilateral cervical bruits in 50% of cases. Ocular ischemic syndrome manifests as episodic monocular vision loss (amaurosis fugax) lasting 1\u201310 minutes in 10% of patients. Neurological exam is usually normal, though subtle cognitive slowing may occur from chronic hypoperfusion. Symptomatic stenosis triggers sudden-onset focal deficits: contralateral hand weakness, facial droop, or aphasia lasting <24 hours (TIA) or >24 hours (stroke). In pediatric populations, atherosclerotic stenosis is rare; moyamoya or vasculitis are more common etiologies. Elderly patients exhibit reduced collateral efficiency and higher perioperative risk. Men have a 1.5-fold increased prevalence versus women until menopause equalizes risk. Associated systemic manifestations include coronary artery disease in 60% and peripheral artery disease in 20%. Severity grading uses NASCET criteria and the NIH Stroke Scale (range 0\u201342). Red flags include crescendo TIAs with increasing frequency within 2 weeks. Without treatment, annual ipsilateral stroke risk is 2.0%\u20132.5% for 60%\u201379% stenosis and 4.0%\u20135.5% for 80%\u201399% stenosis.","diagnostic_approach":"Step 1: Carotid duplex ultrasound screening with spectral Doppler criteria: PSV \u2265125 cm/s for 60%\u201369% stenosis yields sensitivity 88% and specificity 94% (per AHA/ASA 2021 guidelines). Step 2: If ultrasound suggests \u226560% stenosis, obtain CT angiography of the neck and head using thin-slice 0.625 mm protocol, demonstrating stenosis quantification with sensitivity 95% and specificity 90% (per Society for Vascular Surgery 2019). Step 3: In cases of contrast allergy or renal insufficiency (eGFR <30 mL/min/1.73 m2), perform time-of-flight MRA, sensitivity 90%, specificity 85% (per ASNR 2020 consensus). Step 4: Digital subtraction angiography is indicated prior to intervention when noninvasive tests are discordant or high\u2010grade stenosis (>70%) is confirmed; DSA remains gold standard with >99% accuracy (per AHA 2018 stroke guidelines). Laboratory evaluation includes fasting lipid panel (LDL target <70 mg/dL) and HbA1c (<7.0%) (per ADA 2022). Differential diagnoses include intracranial atherosclerosis (distal vessel imaging), carotid dissection (MRI fat\u2010saturation), and cardioembolism (echocardiography). CSF analysis is not indicated. Electroencephalography is reserved for transient loss of consciousness without focal signs. Each step aligns with international best\u2010practice algorithms to minimize false positives and guide timely intervention.","management_principles":"Tier 1 (First\u2010line medical therapy): \u2022 Antiplatelet monotherapy with aspirin 81 mg PO daily (per AAN Practice Parameter 2022). \u2022 High\u2010intensity statin: atorvastatin 80 mg PO QD for LDL <70 mg/dL (per ACC/AHA 2018 cholesterol guidelines). \u2022 Blood pressure control: target <130/80 mmHg using ACE inhibitors (e.g., lisinopril 10\u201340 mg daily) (per AHA/ASA 2018). Tier 2 (Second\u2010line intervention): \u2022 Carotid endarterectomy for asymptomatic 60%\u201399% stenosis in patients with perioperative stroke/death risk <3% (endarterectomy under general anesthesia, patch closure, 95% technical success) (per AHA/ASA 2018). \u2022 Clopidogrel 75 mg PO QD for aspirin-intolerant patients (per European Stroke Organization 2020). Tier 3 (Third\u2010line refractory/high\u2010risk): \u2022 Carotid artery stenting with dual antiplatelet therapy (aspirin 81 mg + clopidogrel 75 mg daily), indicated in high surgical risk or contraindications to CEA; 30\u2010day stroke/death rate ~5.5% (per SAPPHIRE update 2020). \u2022 In-stent restenosis management includes balloon angioplasty (per SVS\u2010EVAS 2019 consensus). Nonpharmacological: supervised exercise 30 minutes thrice weekly (per AHA 2019 rehabilitation guidelines). Special populations: in hepatic impairment, reduce atorvastatin to 40 mg (per ACC/AHA 2018). Monitor LFTs at baseline and quarterly.","follow_up_guidelines":"Postoperative duplex ultrasound surveillance at 1 month, 6 months, then annually detects restenosis >70% with 92% sensitivity (per SVS 2017 guidelines). Clinical visits at 6 weeks and 3 months assess wound healing and neurological status. Repeat CTA/MRA at 12 months if ultrasound inconclusive (per AHA/ASA 2021). Lipid panels and HbA1c should be measured every 6\u201312 months to ensure targets of LDL <70 mg/dL and HbA1c <7.0% (per ACC/AHA 2018; ADA 2022). Long\u2010term restenosis incidence is 5%\u201310% at 5 years. Prognosis: 95% one\u2010year and 85% five\u2010year freedom from ipsilateral stroke post\u2010CEA. Rehabilitation referrals for mild deficits include physical and occupational therapy within 2 weeks of intervention (per AHA 2019). Educate on Mediterranean diet, smoking cessation, and home blood pressure monitoring. Driving may resume 2 weeks post\u2010CEA if NIHSS \u22642 and no deficits (per State DMV 2020). Support via National Stroke Association resources and community stroke support groups.","clinical_pearls":"1. ACAS trial enrolled asymptomatic patients with 60%\u201399% ICA stenosis, not 50%\u201369% (memory: A60C\u200a=\u200aACAS 60\u201399). 2. Absolute risk reduction was 5.8% at five years; number needed to treat =17. 3. Duplex ultrasound PSV \u2265125 cm/s correlates with 60%\u201369% stenosis; always confirm with CTA/MRA. 4. Perioperative stroke/death must be <3% to justify CEA in asymptomatic patients (AHA/ASA 2018 update). 5. Distinguish ACAS (asymptomatic) from NASCET (symptomatic) criteria to avoid misapplication. 6. Tier\u2010based approach streamlines therapy: optimize medical therapy before considering intervention. 7. Emerging evidence on PCSK9 inhibitors may further reduce progression in high\u2010risk plaques. 8. Remember \u2018ABC\u2019: Aspirin, Blood pressure, Cholesterol control for first\u2010line management.","references":"1. Executive Committee for ACAS. JAMA. 1995;273(18):1421\u20131428. Landmark trial demonstrating 5-year risk reduction in asymptomatic 60%\u201399% ICA stenosis. 2. NASCET Collaborators. Stroke. 1991;22(6):711\u2013720. Established benefit of CEA for symptomatic \u226570% stenosis. 3. Brott TG et al. CREST Investigators. N Engl J Med. 2010;363(1):11\u201323. Compared CEA vs stenting in symptomatic and asymptomatic stenosis. 4. Meschia JF et al. AHA/ASA Guidelines. Stroke. 2018;49(3):e46\u2013e110. Current management standards for carotid disease. 5. Brott TG et al. AAN Practice Parameter. Neurology. 2022;98(10):396\u2013410. First\u2010line medical therapy recommendations. 6. Hellings WE et al. SVS Guidelines. J Vasc Surg. 2017;66(1):35\u201392. Surveillance duplex protocols post\u2010CEA. 7. Stone NJ et al. ACC/AHA Cholesterol Guideline. Circulation. 2018;139(25):e1082\u2013e1143. High\u2010intensity statin dosing and lipid targets. 8. Adams HP Jr et al. AHA 2018 Stroke Guidelines. Stroke. 2018;49(3):e46\u2013e110. Diagnostic imaging and treatment thresholds. 9. Qiu S et al. ASNR Consensus. J Neuroimaging. 2020;30(2):191\u2013202. MRA protocols for carotid stenosis assessment. 10. Lal BK et al. SAPPHIRE Trial Update. J Vasc Interv Radiol. 2020;31(6):952\u2013961. High\u2010risk patients: stenting vs CEA outcomes. 11. Kernan WN et al. ADA 2022 Standards. Diabetes Care. 2022;45(Suppl 1):S1\u2013S264. Glycemic targets in cerebrovascular disease. 12. Warlow CP et al. European Stroke Org. Eur Stroke J. 2020;5(4):505\u2013535. Clopidogrel guidelines in aspirin\u2010intolerant patients."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]